News

Zymeworks Engages in Key Investor Conferences for Growth

Zymeworks Engages in Key Investor Conferences for Growth

Zymeworks Highlights Its Upcoming Investor Conferences

Zymeworks Inc., a notable player in the clinical-stage biotechnology sector, is excited to connect with investors through several upcoming conferences. This engagement is crucial for the company’s vision of transforming the treatment landscape for tough diseases, particularly cancer and autoimmune disorders.

Planned Participation in Key Events

The management team at Zymeworks is set to participate in several high-profile investor conferences, providing them an excellent platform to discuss their innovative pipeline and future endeavors:

Jefferies Global Healthcare Conference

On June 4, Zymeworks’ management will engage in one-on-one meetings and will participate in a fireside chat scheduled for 2:35 pm Eastern Time in New York. This event presents a key opportunity to detail the progress of their projects and interact directly with investors.

Goldman Sachs Global Healthcare Conference

Shortly afterward, on June 11 at 2:00 pm Eastern Time, the team will again communicate their advancements at the Goldman Sachs Global Healthcare Conference, also through one-on-one meetings and a fireside chat, this time in Miami.

Citi European Healthcare Conference

Finally, on June 17, the management will take part in one-on-one meetings during the Citi European Healthcare Conference in London, fostering connections and sharing insights about Zymeworks’ commitment to healthcare advancement.

About Zymeworks Inc.

Zymeworks stands out as a global leader in developing multifunctional biotherapeutics aimed at tackling complex diseases. Their mission extends towards making meaningful contributions to improve the lives of patients facing serious health challenges, particularly in the realms of cancer and autoimmune diseases.

With an impressive array of therapeutic platforms and a fully integrated drug development engine, Zymeworks forges paths towards innovative antibody-based treatments. The company has made significant strides with zanidatamab, a HER2-targeted bispecific antibody created using their proprietary Azymetric™ technology.

The pivotal moment came with the accelerated approval of Ziihera® (zanidatamab-hrii), marked as the first dual HER2-targeted bispecific antibody approved for patients with previously treated, unresectable, or metastatic HER2-positive second-line biliary tract cancer in the U.S.

Moreover, zanidatamab is currently undergoing regulatory assessments in Europe and China, affirming Zymeworks’ commitment to expanding access to this groundbreaking treatment.

Advancing Clinical Trials

Zymeworks maintains a robust pipeline of wholly-owned product candidates, showcasing significant potential across various indications. The organization is pushing forward with Phase 1 studies for two investigational drugs, ZW171 and ZW191, while also preparing for an investigational new drug application for ZW251 scheduled for mid-2025.

What sets Zymeworks apart is not just its innovative products but also its strategic partnerships with leading biopharmaceutical firms, which enhance its ability to deliver groundbreaking therapies to the marketplace.

Contact Information

If you have any inquiries about investor relations or media, feel free to reach out:

Investor inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com

Media inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com

Frequently Asked Questions

What are the upcoming events Zymeworks will attend?

Zymeworks will participate in the Jefferies Global Healthcare Conference, the Goldman Sachs Global Healthcare Conference, and the Citi European Healthcare Conference.

What is Zymeworks' primary focus?

The company focuses on developing innovative biotherapeutics for difficult-to-treat conditions, particularly cancer and autoimmune diseases.

What is zanidatamab?

Zanidatamab is a HER2-targeted bispecific antibody developed by Zymeworks, recently approved for the treatment of certain biliary tract cancers.

How does Zymeworks approach drug development?

Zymeworks utilizes a fully integrated drug development engine, allowing for the precision engineering of antibody-based therapies.

How can I get more information about Zymeworks?

For more details, visit their website at www.zymeworks.com or follow them on social media platforms.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 79

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 137

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 171

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 155

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
AI Alliance Rethinks Health Plan Engagement

Updated Category News Views 139

Building Bridges in Healthcare Ever seen healthcare stuck in its own muck with disconnected gears attempting to move the same machine? Well, that's precisely the mountain healthplans.ai and URAWARRIOR aim to climb down from. Founders Rachel Spilo and Dr. Bershan Shaw are gearing up to shake hands in their no-nonsense, real-world vow to sync member engagement with the...

Continue Reading
The Melt Grabs Top Spot in Burger Ratings War

Updated Category News Views 122

Burger Battle: The Melt Claims Victory When you're in the cutthroat world of fast-casual dining, grabbing the top spot on any list is no small potatoes. The Melt did just that, snatching the title of America’s Highest-Rated Burger Spot. Based on an in-depth analysis of Google and Yelp reviews, folks have spoken, loud and clear, over the past two years. It's a world...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 0

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 0

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading

Top 5 Most Recently Viewed Articles

Síminn hf. Achieves Strong Growth in Q2 2025 Results

Updated Category News Views 303

Exciting Financial Highlights from Síminn hf. for Q2 2025 In the second quarter of 2025, Síminn hf. reported remarkable financial growth, demonstrating their resilient operations and commitment to enhancing customer value. The total revenue surged to ISK 7,196 million, marking a 4.7% increase compared to Q2 2024, where revenues stood at ISK 6,871 million. This positive...

Continue Reading
Pacesetter Joins Inc.'s 2026 Best Workplaces List

Updated Category News Views 33

Pacesetter Technology Earns a Spot on Inc.'s Renowned List How many times have we heard companies rattle on about employee satisfaction and culture? But this time, we're talking about a company, Pacesetter Technology, that didn't just talk the talk—they walked right into Inc.'s 2026 Best Workplaces spotlight. And in an era where employers hold all the cards, that's no...

Continue Reading
Discover Meiyume's Innovative Beauty Solutions at Cosmopack

Updated Category News Views 272

Unveiling Meiyume at Cosmopack Asia 2025 Hong Kong, leading the way in beauty solutions, is set to host an influential event as Meiyume showcases its innovative initiative titled SEEDED — Rooted in Intelligence, Connected Through the Beauty Vein at Cosmopack Asia. With a strong foothold in packaging and product development, Meiyume leverages its proprietary Beauty...

Continue Reading
MAHA Action, Inc. Announces Support for Zach Lahn's Governor Bid

Updated Category News Views 215

MAHA Action, Inc. Endorses Zach Lahn for Iowa Governor MAHA™ Action, Inc., a prominent advocate for health freedom, proudly announces its endorsement of Zach Lahn as the next Governor of Iowa. Lahn has launched an Iowa First platform aimed at empowering residents and improving personal liberties. Commitment to Health Freedom Lahn has emerged as a vigorous champion of...

Continue Reading
Couchbase Reports Impressive Q1 Earnings Amid Rising Demand

Updated Category News Views 309

Financial Performance Highlights for Couchbase Couchbase, Inc. (NASDAQ: BASE), the leading developer data platform that powers critical applications in today’s AI-driven world, has unveiled its financial performance for the first quarter ended April 30, 2025. With a remarkable increase in revenue and strong annual recurring revenue (ARR), Couchbase has demonstrated the...

Continue Reading